Learning Objectives:
Upon successful completion of this application-based course pharmacists should be able to:
-
Describe the mechanism by which chimeric antigen receptor (CAR) T-cell therapy is used in cancer treatment
-
Assess the efficacy of CAR-T cell therapy in cancer treatment
-
Identify toxicities of CAR T-cell therapy and implement appropriate managem
-
Design an appropriate antimicrobial prophylaxis regimen for patients receiving CAR T-cell therapy
Claim your CPE Credit
To obtain 1.0 contact hour of continuing pharmacy education credit (0.1 CEU), participants must participate in the live activities, and logon to the CEimpact website to complete the exam and evaluation.
- Go to https://learn.ceimpact.com and login to CEImpact
- If you are new to the site, click on Create an account before logging in.
- Enter the course code (provided at the end of the lecture) in the text box on the left of the screen and click Submit.
- Click on My Courses (on the left of the screen) to locate the course.
- Click on the course title to access the course.
- Complete the exam and evaluation as prompted and click Submit.
- The course will move to the Completed tab under My Courses.
- The CPE Statement of Credit will be available on CPE Monitor, www.MyCPEMonitor.net.
CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0107-9999-22-413-L01-P | 0.1 CEUs/1.0 Hrs.
Live Date: December 15, 2022
Live Expiration: January 14, 2023
Faculty Disclosure: Michelle She has no relevant financial relationships with ineligible companies to disclose. Erica Wass is on the speakers' bureau of Omeros Inc, a biotech company. All financial relationships have been mitigated.
Course Format: Live
Financial Support: None
Course Fee: None